Campylobacter pylori – A Role in Non-Ulcer Dyspepsia?

Lambert, John; Dunn, Kathleen; Borromeo, M.; Korman, M. G.; Hansky, J.

doi:10.3109/00365528909091728

Cited by 81 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure 1 also shows that the 99% CIs in the published studies of nonulcer dyspepsia involve more than 2-fold uncertainty owing to the small numbers of patients: for example, only 2 studies 27,38 involved more than 100 patients and 100 controls. But, although a previously published meta-analysis 10 pooled the results of 19 published studies involving a total of 2700 patients with nonulcer or uninvestigated dyspepsia to report a combined OR of 2.3 (95% CI, 1.9-2.7) for H pylori infection in dyspepsia, its conclusions are potentially misleading * References 28,29,31,33,36,37,39,40,44,45,48,49. Olmos et al, 27 1998…”

Section: Statistical Analysesmentioning

confidence: 97%

Systematic Review of the Epidemiological Evidence on Helicobacter pylori Infection and Nonulcer or Uninvestigated Dyspepsia

Danesh¹,

Lawrence²,

Murphy³

et al. 2000

Arch Intern Med

View full text Add to dashboard Cite

show abstract

Section: Statistical Analysesmentioning

confidence: 97%

Systematic Review of the Epidemiological Evidence on Helicobacter pylori Infection and Nonulcer or Uninvestigated Dyspepsia

Danesh¹,

Lawrence²,

Murphy³

et al. 2000

Arch Intern Med

View full text Add to dashboard Cite

show abstract

“…191,192,203 There was no asymmetry in the Egger plot (p = 0.8), all the trials being about the same size.…”

Section: Reasons For Heterogeneitymentioning

confidence: 99%

“…Two trials included both H. pylori-positive and -negative individuals and these groups were entered separately to evaluate any difference in outcome according to infection status. 191,192 Six trials reported global dyspepsia improvement as a dichotomous outcome [187][188][189][190]192 and there was a trend towards bismuth salts being more effective than placebo, although this was of marginal statistical significance (RR reduction, 40%; 95% CI, -3 to 65) (Figure 10). Again, significant heterogeneity was noted in the analysis (Q = 18.31; df = 5; p = 0.003), due to the inclusion of one trial 190 with a very low placebo response rate (5%) and a correspondingly large treatment effect (RR reduction, 79%).…”

Section: Bismuth Saltsmentioning

confidence: 99%

“…[186][187][188][189][190][191][192] All reported global dyspepsia symptom scores. The majority of the trials evaluating bismuth assessed the role of H. pylori eradication in NUD.…”

Section: Bismuth Saltsmentioning

confidence: 99%

“…There was no obvious relationship between H. pylori status and effectiveness. 191,192 Other pharmacological agents There were two trials in which the antimuscarinic, pirenzepine, was compared with placebo in a total of 163 patients. 193,194 Both reported improvements in global dyspepsia symptoms as a dichotomous variable.…”

Section: Figure 7 Meta-analysis Of Efficacy Of Prokinetic Therapy (Drmentioning

confidence: 99%

See 2 more Smart Citations

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Competing interests: R Hobbs is a board member of the European Society of Primary Care Gastroenterology, and has received sponsorship for travel and honoraria from a number of biotechnology and pharmaceutical companies for plenary talks and attendance at major scientific congresses and conferences. HTA Published end of 2000This report should be referenced as follows:Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and ...

show abstract

Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori. Ulcer history as an explanation of an apparent association

Schlemper¹

1995

Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

Campylobacter pylori – A Role in Non-Ulcer Dyspepsia?

Cited by 81 publications

References 24 publications

Systematic Review of the Epidemiological Evidence on Helicobacter pylori Infection and Nonulcer or Uninvestigated Dyspepsia

Systematic Review of the Epidemiological Evidence on Helicobacter pylori Infection and Nonulcer or Uninvestigated Dyspepsia

The management of dyspepsia: a systematic review.

Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori. Ulcer history as an explanation of an apparent association

Contact Info

Product

Resources

About